Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Pharma Well Oy
OY
Active
Y-tunnus 3312680-6
Telinetie 5A-56, 33880
Lempäälä
Non-specialised wholesale trade
·
NACE 4690
Est. 2022 · 3 years old
— employees
www.pharmawell.fi
Share
Finland
/
Companies
/
Non-specialised wholesale trade
/
Pharma Well Oy
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
EUR millions
1M
1M
1M
0M
0M
2023: 1M
1M
2023
2024: 1M (0% vs 2023)
1M
0%
2024
2025: 1M (0% vs 2024)
1M
0%
2025
EBITDA
EUR millions
0M
0M
0M
-1M
-1M
2023: 0M
0M
2023
2024: 0M
0M
2024
2025: 0M
0M
2025
Income statement
EUR thousands
Item
2025
2024
2023
Revenue
1 156
1 011
1 336
Staff expenses
−187
−224
−208
EBITDA
−73
−71
−2
Depreciation & amort.
−2
−2
−1
EBIT
−75
−73
−4
Net financials
−1
−9
−4
Profit before tax
−77
−82
−7
Tax
−0
−0
−0
Net profit
−77
−82
−7
Balance sheet
EUR thousands
Item
2025
2024
2023
Total assets
234
281
639
Equity
39
115
53
Long-term debt
0
0
0
Short-term debt
195
166
586
Total debt
195
166
586
Financial ratios
5-year trend
EBITDA margin
−6,4 %
This company
15,8 %
Market median
This company
Market median
141% below market
2023
2025
Equity ratio
16,5 %
This company
38,2 %
Market median
This company
Market median
57% below market
2023
2025
Return on equity
−198,1 %
This company
18,4 %
Market median
This company
Market median
>999% below market
2023
2025
Net profit margin
−6,6 %
This company
8,1 %
Market median
This company
Market median
181% below market
2023
2025
Asset turnover
4,95×
This company
1,12×
Market median
This company
Market median
342% above market
2023
2025
Debt / equity
5,04×
This company
0,62×
Market median
This company
Market median
713% above market
2023
2025
Annual reports & filings
Annual report 2025
Filed via PRH / YTJ · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via PRH / YTJ · Period 2022-09-18 – 2023-12-31
View
PDF
More on Pharma Well Oy
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network